Transdermal NES-Testosterone Gel for Sperm Suppression Balance

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing male contraceptive methods are limited, inconvenient, and often result in undesirable side effects, with a need for a safe, effective, and reversible method that maintains testosterone levels within the normal range while reducing sperm count.

Innovation Solution

A transdermal composition comprising 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione (NES) and testosterone (T) in specific ratios, applied as a hydroalcoholic gel, to suppress gonadotropins and sperm concentration without significant side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high doses of testosterone are used to suppress sperm production, then contraceptive effectiveness is improved, but testosterone levels become excessively high causing side effects

Engineering Contradiction:
Improvecontraceptive effectivenessVSAvoidexcessive testosterone levels and side effects
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the parameter of testosterone dosage by using low-dose testosterone (62.5-100 mg) in combination with progestin, rather than high doses alone. This parameter adjustment allows suppression of sperm production while maintaining testosterone levels within the normal physiological range, avoiding excessive side effects.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite hormonal formulation combining testosterone with progestin (NES) in specific ratios. This composite approach leverages the synergistic effect of both hormones to achieve effective sperm suppression while the progestin component helps regulate testosterone levels and reduce androgenic side effects.

Inventive Principle:
Principle #40Composite materials

2Ease of operation

If testosterone replacement therapy is used to treat hypogonadism, then libido and sexual function are improved, but sperm production is inhibited

Engineering Contradiction:
Improvelibido and sexual functionVSAvoidsperm production
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent adjusts the parameter of testosterone dosage to low-dose ranges (62.5-100 mg) that are sufficient to treat hypogonadism symptoms but not high enough to completely inhibit sperm production. This parameter optimization allows simultaneous improvement of sexual function and maintenance of fertility potential.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a dynamic hormonal balance by combining testosterone with progestin, where the progestin component modulates the androgenic effects. This dynamic interaction allows the formulation to treat hypogonadism symptoms while maintaining reversible suppression of spermatogenesis, enabling future fertility restoration.

Inventive Principle:
Principle #15Dynamics

3Reliability

If progestin is added to testosterone to suppress gonadotropins, then sperm concentration is reduced, but the formulation complexity increases

Engineering Contradiction:
Improvesperm concentration suppressionVSAvoidformulation complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges testosterone and progestin into a single transdermal gel formulation, combining two hormonal components in one application. This merging simplifies the delivery system compared to separate injections or multiple applications, while achieving effective gonadotropin suppression and sperm concentration reduction.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The patent optimizes the parameter ratios of testosterone to progestin in the formulation, using specific concentrations (e.g., 62.5-100 mg testosterone with corresponding progestin amounts). This parameter optimization ensures effective sperm suppression while maintaining formulation stability and ease of application.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively suppresses sperm concentration while maintaining testosterone levels within the normal range, with minimal side effects, offering a convenient and reversible contraceptive option.

Implementation Method 1

transdermal composition comprising 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione... testosterone... applied as a hydroalcoholic gel

Methodology Applied
Scientific EffectTransdermal absorption: Absorption (physical)

Data Source

PatentUS12502395B2Progestin/testosterone transdermal gel
Publication Date: 2025.12.23 POPULATION COUNCIL INC
  • US12502395B2 patent drawing

AI summary

The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.